Patents by Inventor Liangqin Guo

Liangqin Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 12264134
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 1, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
  • 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
    Patent number: 12246008
    Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: March 11, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Christopher J. Bungard, Helen Y. Chen, Jason M. Cox, Liangqin Guo, Michael J. Kelly, III, Ronald M. Kim, Mark E. Layton, Hong Liu, Jian Liu, Mehul F. Patel, James J. Perkins, Deping Wang, Walter Won, Younong Yu, Ting Zhang
  • PCSK9 antagonist compounds
    Patent number: 12178842
    Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: December 31, 2024
    Assignee: MERCK SHARP & DOHME LLC
    Inventors: Hubert Josien, Abbas Walji, Harold B. Wood, Fa-Xiang Ding, Jian Liu, Thomas Joseph Tucker, Michael Man-Chu Lo, Liangqin Guo
  • Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 12152019
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: November 26, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Li Xiao, Wensheng Yu
  • Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 12091405
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 17, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, David Sloman, Li Xiao, Wensheng Yu, Rui Zhang
  • Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 12065438
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: August 20, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yongxin Han, David Jonathan Bennett, Indu Bharathan, Liangqin Guo, Brett A. Hopkins, Xianhai Huang, Derun Li, Min Lu, Alexander Pasternak, David L. Sloman, Hongjun Zhang, Hua Zhou
  • POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA
    Publication number: 20240018145
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing influenza. The compounds are cap-dependent endonuclease inhibitors.
    Type: Application
    Filed: July 22, 2021
    Publication date: January 18, 2024
    Applicants: Merck Sharp & Dohme LLC, COCRYSTAL PHARMA, INC.
    Inventors: Yonglian Zhang, John A. McCauley, Michael Man-Chu Lo, Liangqin Guo, Kake Zhao, Frank Bennett, Ronald M. Kim, Reynalda Keh DeJesus, Valerie W. Shurtleff, Manuel de Lera Ruiz, Michael Plotkin, Hua Su, James Fells, Brendan M. Crowley, Harry R. Chobanian, Mark W. Embrey, Gregori J. Morriello
  • PCSK9 ANTAGONIST COMPOUNDS
    Publication number: 20230165932
    Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Application
    Filed: October 31, 2022
    Publication date: June 1, 2023
    Inventors: Hubert Josien, Abbas Walji, Harold B. WOOD, Fa-Xiang Ding, Jian Liu, Thomas Joseph Tucker, Michael Man-Chu Lo, Liangqin Guo
  • NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20230008022
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: November 25, 2019
    Publication date: January 12, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
  • PCSK9 antagonist compounds
    Patent number: 11484565
    Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: November 1, 2022
    Assignee: MERCK SHARP & DOHME LLC
    Inventors: Hubert Josien, Abbas Walji, Harold B. Wood, Fa-Xiang Ding, Jian Liu, Thomas Joseph Tucker, Michael Man-Chu Lo, Liangqin Guo
  • [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 11478461
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 25, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Liangqin Guo, Hongjun Zhang, Ping Chen, Dane Clausen, Xavier Fradera, Yongxin Han, Shuwen He, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Li Xiao, Feng Ye
  • Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 11352320
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: June 7, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Shuwen He, Dane Clausen, Liangqin Guo, Yongxin Han, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Dong Xiao, Li Xiao, Feng Ye, Hongjun Zhang
  • 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
    Publication number: 20220000844
    Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.
    Type: Application
    Filed: December 2, 2019
    Publication date: January 6, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Bungard, Helen Y. Chen, Jason M. Cox, Liangqin Guo, Michael J. Kelly, III, Ronald M. Kim, Mark E. Layton, Hong Liu, Jian Liu, Mehul F. Patel, James J. Perkins, Deping Wang, Walter Won, Younong Yu, Ting Zhang
  • NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210403469
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: November 1, 2019
    Publication date: December 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, David Jonathan Bennett, Indu Bharathan, Liangqin Guo, Brett A. Hopkins, Xianhai Huang, Derun Li, Min Lu, Alexander Pasternak, David L. Sloman, Hongjun Zhang, Hua Zhou
  • Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors
    Publication number: 20210393600
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: April 15, 2019
    Publication date: December 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Liangqin Guo, Hongjun Zhang, Ping Chen, Dane Clausen, Xavier Fradera, Yongxin Han, Shuwen He, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Li Xiao, Feng Ye
  • NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210395240
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 28, 2019
    Publication date: December 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, David Sloman, Li Xiao, Wensheng Yu, Rui Zhang
  • NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210380572
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 11, 2019
    Publication date: December 9, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Li Xiao, Wensheng Yu
  • NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210330676
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: August 16, 2019
    Publication date: October 28, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Nunzio Sciammetta, Andreas Verras, Li Xiao, Wensheng Yu, Rui Zhang
  • NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20210198190
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: May 28, 2019
    Publication date: July 1, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Shuwen He, Dane Clausen, Liangqin Guo, Yongxin Han, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Dong Xiao, Li Xiao, Feng Ye, Hongjun Zhang
  • Substituted N?-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors
    Patent number: 11034661
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 15, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Liangqin Guo, Yongxin Han, Kun Liu, Shuwen He, Joseph Kozlowski, Ravi Nargund, Wensheng Yu, Hongjun Zhang, Qinglin Pu, Derun Li, Abdelghani Achab, Guoqing Li